TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

February 27, 2024

https://www.globenewswire.com/news-release/2024/02/27/2835897/8790/en/TG-Therapeutics-Announces-Issuance-of-Additional-Patents-for-BRIUMVI-ublituximab-xiiy.html

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ:TGTX) (TG) today announced the issuance of three additional patents by the United States Patent and Trademark Office (USPTO) for BRIUMVI® (ublituximab-xiiy), the first and only anti-CD20 monoclonal antibody approved in the US for patients with relapsing forms of multiple sclerosis (RMS) that can be administered in a one-hour infusion following the starting dose.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.